Sanofi

Cell Pathways

Novarock Biotherapeutics, Ltd.

Han Li

Nicolas Baurin

W Joseph Thompson

Dorothea Kominos

Alla Pritsker

Haichun Huang

Govindan Subramanian

Ming Lei

Matthew Davison

Yi Pei

Xin Chen

Jie Zhang

Li Liu

Rifat Pamukcu

Gary A Piazza

Philip Janiak

Magali Mathieu

Alexey Rak

Bruno Poirier

Robert E Bellet

Francis Duffieux

Cyril Daveu

Christopher Ryan Morgan

Jae-Won Soh

I Bernard Weinstein

Patrick Grailhe

John R Fetter

Bing Zhu

The present disclosure provides antibodies and antibody fragments thereof that bind to IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-23 receptor signaling axis and are therefore useful for the treatment of immune-mediated inflammatory disorders.

Anti-interleukin-23 P19 antibodies and methods of use thereof

Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.

Anti-CLauDiN 18 antibodies and methods of use thereof

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg-Bradykinin and des-Arg-Kallidin-like peptide.

Nucleic acids encoding antibodies to Kallidin and des-Arg-Kallidin and host cells comprising the same

[object Object]

The invention provides antibodies that specifically bind to Plasminogen Activator Inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof

This invention provides a method to identify compounds potentially useful for the treatment and prevention of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with its ability to elevate JNK kinase activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibition, an ability to elevate JNK kinase activity, growth inhibition and apoptosis induction are desirable for the treatment of neoplasia.

Method for screening compounds for the treatment of neoplasia

A method of treating renal cell carcinoma in a mammal with that disease comprising administering to the mammal a physiologically effective amount of an inhibitor of PDE10.

Methods for treatment of renal cell carcinoma

A method for identifying compounds useful for the treatment of neoplasia involves acertaining whether such compounds exhibit an ability to inhibit a PDE that is characterized by cGMP specificity, cooperative kinetic behavior and insensitivity to phosphorylation.

Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia

A method for selecting compounds for the treatment of neoplasia includes assessing whether the compounds cause an increase in PKG activity in the neoplasia of interest.

Method for selecting compounds for inhibition of neoplastic lesions

Growing community of inventors

Yardley, PA, United States of America

Han Li